OTR Acquisition Corp.

admitted from EDGAR's QUARTERLY FORM INDEX, walked without any SIC filter. The SIC 6770 census could not reach this registrant: EDGAR reassigns a shell's SIC the day it stops being one, and this CIK now files under 2834 (Pharmaceutical Preparations). The screen found it by filing SHAPE instead — S-1 2020-08-18 → 8-A12B 2020-11-16 → 424B4 2020-11-19 — which nothing rewrites. Admission rule: src/lib/universe-admit.ts. SIC 2834 + self-described blank check in 424B4 0001104659-20-127025; 424B 0001104659-20-127025 priced 2020-11-19 under S-1 0001104659-20-096242 (file 333-248093, an offering for cash); common ticker OTRA off 10-Q 0001410578-22-001479 (2022-05-13); lifecycle EXITED. The pricing prospectus was filed under SEC file number 333-248093, which belongs to S-1 0001104659-20-096242 (2020-08-18) — a registration of shares sold for CASH, which is what makes it an IPO rather than merger consideration. Blank-check status from the registrant's own first-person sentence in that prospectus (EDGAR full-text search, 424B4 2020-11-19). Ending PROVEN, not inferred: CLOSED per Form 25 0001354457-22-000310 (2022-05-19) — Form 25 filed under 17 CFR 240.12d2-2(a)(3) — the rule for securities that "have come to evidence other securities in substitution therefor", i.e. the shares became the successor's (class: OTR Acquisition Corp. Class A Common Stock, Warrants, and Units); the successor registrant Comera Life Sciences Holdings, Inc. (CMRA) (CIK 0001907685) filed an 8-K carrying item 2.01 (Completion of Acquisition) naming "OTR Acquisition Corp." — the SPAC merged into a new registrant and so filed no closing report of its own. ipoSizeM and deadline left NULL: gross-proceeds prose conflates the over-allotment with the offering, and a charter deadline belonging to a vehicle that has ended is a date nobody can act on. ipoDate is the 424B pricing date.

warrantStrike=11.5, warrantCallPrice=18, unitSeparationDays=52 from the definitive prospectus (0001104659-20-127025). NOT FILLED: rightShareRatio — no stated candidate

sponsor "OTR Acquisition Sponsor LLC" sourced from prospectus definition (10-K/A) acc 0001104659-21-068910.

[CLOSED-2.01] SEC accession 0001104659-22-064268 (Form 8-K, item 2.01 Completion of Acquisition or Disposition of Assets); the cover's date of earliest event reported is 2022-05-19. That is the SEC's own date for this report and NOT necessarily the closing day — an 8-K may cover several events, and where the two differ the closing date is in the quoted sentence below. Target read STRUCTURALLY from the merger agreement's party list — the party that is neither the registrant (identified by the filing's own cover page) nor a merger sub (identified by the clause making it a subsidiary of another party) nor an accommodation party (identified by a "solely for purposes of" joinder), and it was the only one left. The same party list also names "Comera Life Sciences, Inc.", which differ from the recorded target only in legal form and are treated as the same identity; the first-named spelling is the one recorded. The sentence it was read from: "¨ Introductory Note On May 19, 2022, Comera Life Sciences Holdings, Inc., a Delaware corporation (" Holdco "), consummated the acquisition of all of the issued and outstanding shares of OTR Acquisition Corp., a Delaware corporation (" OTR ") and Comera Life Sciences, Inc., a Delaware corporation (" Comera "), in accordance with that certain Business Combination Agreement, dated as of January 31, 2022 (as amended, the " Business Combination Agreement "), by and among Holdco, OTR, Comera, CLS Sub Merger 1 Corp., a Delaware corporation, (" Comera Merger Sub "), and CLS Sub Merger 2 Corp., a Delaware corporation (" OTR Merger Sub ")." No deal value is set — an item-2.01 heading is not a figure. No date column is set: Deal has announcedAt, voteDate and expectedCloseAt and nowhere to record an actual close, so the SEC's date is kept here until that column exists.

entity created from the filed target name; no About paragraph on file, so every other field awaits a sourced read

OTHER -> BIOTECH, on DEFM14A 0001193125-22-106541: "Comera is a pre-clinical biotechnology company dedicated to promoting a compassionate new era in medicine by applying a deep knowledge of formulation science an"